BioLargo® Spotlight: Odor-No-More® Leverages Turn-Key Engineering Services and Top-Performing Products for Unsurpassed Industrial Odor and VOC Control

BioLargo is a unique company in many ways, the most notable of which is our structure – we are an emerging, publicly-held company with multiple separate and unique business units. BioLargo® Water develops our disruptive and wide-reaching AOS water treatment system, Odor-No-More manufactures and sells CupriDyne® Clean Industrial Odor Eliminator, BioLargo Engineering, Science & Technologies^tm (BLEST) is our full-service environmental engineering company, and Clyra Medical Technologies^tm features our revolutionary wound care technology. What many people don’t realize about this unique structure is the tremendous opportunity for synergy between business units, and how this synergy can and does grant us access to vertical market segments that we would not otherwise have access to.

A great example of this is unfolding right now. If you follow our disclosures, you’ll know that our subsidiary Odor-No-More has, in the past few quarters, enjoyed significant and growing success selling its industrial odor control chemistry solution CupriDyne Clean to the municipal solid waste (MSW) and wastewater treatment industries due to its superior performance and price advantage over competing products. Now, however, we are expanding our business strategy whereby to bidding (and winning) on contracts to design, build, and install (DB&I) custom misting systems for our odor control clients, with the design component being handled in-house by our very own BLEST engineering team. The addition of the BLEST team enables us to offer unparalleled engineering quality and precision vs. our competitors, making this a unique and powerful example of inter-subsidiary synergy.

At the request of our clients, we (Odor-No-More) and BLEST have put out more than 20 bids on misting system design, build, and install (DB&I) contracts, and have recently started to win contracts to build, install, and service customized misting systems designed by BLEST. These custom misting systems grant our customers unparalleled odor control delivery that is perfectly suited for their needs, rather than being “one size fits all” delivery systems. Consequently, our customers’ odor problems are more efficiently mitigated, and less chemistry is wasted. These misting systems are also, naturally, designed to be used with our own CupriDyne Clean, and management expects that these contracts will result in additional increases in product sales over the coming months and years.

In one more specific example of this, we recently put out a bid on a large contract to install custom misting systems on the trash compactors of more than 200 locations of a nation-wide retail chain. This is a perfect example where synergy with BLEST has led to Odor-No-More’s enhanced offerings attracting large potential customers. This contract and more have the potential to grow Odor-No-More, BLEST, and BioLargo enormously, which is why this strategy is key to our success.

As we march forward, we will continue to highlight our continuing integration of technology, products and services to serve customers with solutions that work and provide unsurpassed value.  

What is a BioLargo Spotlight?

It’s an exciting time at BioLargo. We’re moving fast, and it can be difficult to keep our stockholders and the investing public informed of our progress. In light of this, we will be posting a series of short articles titled “BioLargo Spotlight”, highlighting certain business activities and other important information in between our required SEC filings. Of course, these do not replace our public filings, which contain more complete information than can be delivered in this forum, and thus we urge you to carefully read and rely on those filings for definitive information, and to review our risk factors and caution regarding forward-looking statements. We are optimistic about our business as we work hard to continue to grow and ultimately generate profits for our stockholders.   

Legal Disclaimer

Our attorneys remind us that while we believe these developments are important and that these small victories could add up and lead to big victories, at this stage they do not rise to the level of an official material disclosure. As the size and magnitude of these developments become material, we will naturally report that information in an 8-K and our regular SEC filings.

BioLargo Spotlight Blog Post: Toxicity Studies

As our AOS water treatment system progresses toward commercialization, one of the standard questions I am often asked is whether there are potential adverse effects of AOS-treated water on aquatic organisms and the environment. As a word to the uninitiated, every water treatment technology must answer this question before it goes commercial. It might seem counter-intuitive that it’s necessary to prove that a water treatment technology doesn’t make toxic water, but it’s necessary to demonstrate to regulatory agencies that whatever magic goes on inside your treatment device doesn’t convert water contaminants into toxic compounds. In the the industry, these are commonly known as disinfection and decontamination by-products (DBPs), and it’s necessary for every technology to prove that their DBPs are either minimal or mitigated, and that they’re not toxic.

Thankfully, things look good for the AOS – all prior tests using cultured human cells suggest that AOS-treated water isn’t toxic. Next, we are working to prove that AOS-treated water isn’t toxic to aquatic life, which is both industry standard and necessary to progress to the commercial stage. To do this, a collaboration has been established with the University of Alberta’s Dr. Greg Goss. Dr. Goss is an expert on water quality assessment using aquatic models and has previously worked on similar projects with other companies. This project, funded by the National Engineering Research Council (NSERC) of Canada, will evaluate whether long-term exposure to AOS-treated water results in any adverse effect(s) on aquatic organisms. Either rainbow trout and/or water fleas will be exposed to AOS-treated municipal wastewater effluent and the effects on reproductive fecundity and/or gene expression will be compared to trout and water fleas exposed to the same wastewater, but untreated. Furthermore, using municipal wastewater effluent spiked with known environmental contaminants, it will be possible to demonstrate if the AOS actually provides protection from the effects of known contaminant on these organisms. 

Rainbow trout

 

Water flea

We’re confident that the results of this study will provide the necessary evidence of the environmental safety of our innovative AOS technology. This work provides one more piece of the puzzle required for safe implementation of the AOS to provide reliable and cost-efficient water treatment to multiple industries and applications. These results will also empower us in our progress toward taking the AOS to market, as they represent a necessary and important milestone for its commercialization.

Dr. Laura Patterson-Fortin

Lead Disinfection Research Scientist and Co-CSO

What is a BioLargo Spotlight?

It’s an exciting time at BioLargo. We’re moving fast, and it can be difficult to keep our stockholders and the investing public informed of our progress. In light of this, we will be posting a series of short articles titled “BioLargo Spotlight”, highlighting certain business activities and other important information in between our required SEC filings. Of course, these do not replace our public filings, which contain more complete information than can be delivered in this forum, and thus we urge you to carefully read and rely on those filings for definitive information, and to review our risk factors and caution regarding forward-looking statements. We are optimistic about our business as we work hard to continue to grow and ultimately generate profits for our stockholders.   

Legal Disclaimer

Our attorneys remind us that while we believe these developments are important and that these small victories could add up and lead to big victories, at this stage they do not rise to the level of an official material disclosure. As the size and magnitude of these developments become material, we will naturally report that information in an 8-K and our regular SEC filings.